Combining antimicrobial peptides with antibiotics and delivering them via nanoparticles, hydrogels, or microneedle patches could create synergistic therapies that overcome antibiotic resistance.
Membrane disruptionAMPs primarily kill bacteria by disrupting their cell membranes — a mechanism fundamentally different from conventional antibiotics that makes resistance development much less likely
What the researchers found
Antimicrobial peptides (AMPs) and peptidomimetics can be combined with conventional antibiotics, quorum sensing inhibitors, metal nanoparticles, and photoresponsive materials to create synergistic therapies that overcome antibiotic resistance. AMPs work primarily by disrupting bacterial cell membranes — a mechanism fundamentally different from conventional antibiotics — which gives them broad-spectrum activity and lower risk of resistance development.
Advanced delivery systems including nanoparticles, hydrogels, microneedle patches, and inhaled formulations can enhance AMP targeting, prolong therapeutic duration, and reduce systemic toxicity. The review argues that combining AMPs with other antimicrobial agents through smart delivery platforms represents the most promising strategy for addressing the global antibiotic resistance crisis.
Why it matters
Antibiotic resistance kills over 1.2 million people annually and new antibiotic development has nearly stalled. AMPs attack bacteria through mechanisms that are much harder to develop resistance against, but they struggle with stability, toxicity, and delivery when used alone. Combining them with conventional drugs and modern delivery systems could create therapies that are both more effective and harder for bacteria to resist — potentially our best weapon in the post-antibiotic era.
The numbers in context
Delivery systems: nanoparticles + hydrogels + microneedle patches + inhaled formulations · Combinations: antibiotics + quorum sensing inhibitors + metal nanoparticles + photoresponsive materials
How the study worked
Comprehensive review covering AMP structure-dependent antimicrobial mechanisms, synergistic combination therapy strategies, and drug delivery system technologies, with case studies from recent literature.
Who was studied
Not applicable — review of antimicrobial peptide combination therapies and delivery technologies
What this study cannot tell us
As a review, this synthesizes existing research rather than generating new data. Most AMP combination therapies and advanced delivery systems are in preclinical stages. The gap between promising lab results and approved clinical therapies remains wide, with challenges including manufacturing scalability, regulatory pathways for combination products, and cost of complex delivery systems.
How to read the evidence
This is a comprehensive review in the Journal of Materials Chemistry B covering the intersection of AMP biology and delivery technology. While it provides an excellent landscape overview, most approaches discussed are preclinical.
When this study was published
Published in 2025 in Journal of Materials Chemistry B. Extremely current, capturing the latest advances in AMP combination therapies and delivery systems.
The bigger picture
The antibiotic resistance crisis has pushed the WHO to list AMPs as a priority area for new antimicrobial development. This review maps the convergence of three fields — peptide biology, combination pharmacology, and nanotechnology-based drug delivery — into an integrated strategy for the post-antibiotic era. The approach of combining AMPs with conventional drugs through advanced delivery systems could yield therapies that are greater than the sum of their parts.
Questions still open
- Which AMP-antibiotic combinations show the strongest synergistic effects against specific drug-resistant bacteria?
- Can nanoparticle and hydrogel delivery systems be manufactured at scale and at costs competitive with conventional antibiotics?
- How close are AMP combination products to entering human clinical trials?
Common questions
Why are antimicrobial peptides harder for bacteria to resist than antibiotics?
Why combine AMPs with other drugs instead of using them alone?
Read the original research
Combating the post-antibiotic era crisis: antimicrobial peptide/peptidomimetic-integrated combination therapies and delivery systems.
Journal of materials chemistry. B, 13(38), 11996-12019
Citation
Chi, Jiaying; Lin, Qiaoni; Jin, Bingrui; Ou, Jiayu; Jiang, Ling; Yang, Xinyu; Guo, Jialiang; Peng, Tingting; Lu, Chao. (2025). Combating the post-antibiotic era crisis: antimicrobial peptide/peptidomimetic-integrated combination therapies and delivery systems.. Journal of materials chemistry. B, 13(38), 11996-12019. https://doi.org/10.1039/d5tb01424g